Somatrogon (Ngenla®). HTA ID: 22010

Assessment Status Rapid review complete
HTA ID 22010
Drug Somatrogon
Brand Ngenla®
Indication For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone
Assessment Process
Rapid review commissioned 15/02/2022
Rapid review completed 25/03/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that somatrogon be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement – November 2022.